JPMorgan raised the firm’s price target on Denali Therapeutics to $29 from $28 and keeps an Overweight rating on the shares. The analyst increased the probability of sucess for the company’s engineering brain delivery efforts in neuronopathic lysosomal storage diseases beyond DNL310 in Hunter Syndrome.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- JPMorgan smid & large cap biotech analysts hold analyst/industry conference call
- Denali Therapeutics says FDA selects DNL126 for START Pilot Program
- Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies